1. Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma

3. Introduction

4. Introduction (cont)

5. The Role of IL-5

6. Anticytokines Against IL-5

7. Anti-IL-5 Therapy

8. Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

9. Mepolizumab

10. Severe Asthma Phenotypes

11. Severe Asthma Phenotypes: T2-High Inflammation

12. Eosinophils and Exacerbation Rate Reduction on Mepolizumab

13. Severe Asthma Phenotypes: Th2-Low Inflammation

14. Investigational Agents: T2 Low Asthma

15. How Common Is Th2 (IL-13) High in Severe Asthma? U-BIOPRED

16. Mechanisms of Severe Eosinophilic Asthma

17. Definition of Severe Asthma

18. GINA Treatment Recommendations 2018

19. Uncontrolled Asthma

20. Which Comorbidities Can Affect Asthma?

21. Re-Evaluation of Diagnosis in Adults With Physician-Diagnosed Asthma

22. Risk for Exacerbation and Blood Eosinophils (Mepolizumab vs Placebo)

23. Mepolizumab vs Placebo in the DREAM Trial

24. T2 Status and Exacerbation Rate

25. Anticytokines Against IL-5 (cont)

26. GINA Treatment Recommendations 2018 (cont)

27. Mepolizumab (cont)

28. Reslizumab

29. T2 Status and Exacerbation Rate

30. Omalizumab Reduces the Requirement for OCS

31. Benralizumab

32. U-BIOPRED Patients With Severe Asthma: Requirement for Anti-IgE or Anti-IL-5 Antibody Treatments

33. Anticytokines Against IL-5 (cont)

34. Effect of Mepolizumab on QoL

35. The Effect of Omalizumab on Asthma Exacerbations Over a Year

36. Conclusions

37. Abbreviations

38. Abbreviations (cont)